BridgeMD
A Study of Amivantamab in Addition to Standard of Care Agents Compared with Standard of Care in Participants With Recurrent/Metastatic Head and Neck Cancer
EU CTIS ID: 2025-521917-24-00
What this study is testing
To compare anti-tumor activity
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1. Have histologically or cytologically confirmed R/M HNSCC that is considered incurable by local therapies.
- 2. Be treatment-naïve for systemic therapy in the R/M setting.
- 3. 18 years and older with ECOG 0-1
- 4. Have measurable disease according to RECIST v1.1
You likely can't join if
- 1. Uncontrolled illness
- 2. Has untreated brain metastases or history or known presence of leptomeningeal disease
- 3. Has a history of clinically significant cardiovascular disease
- 4. Inadequate organ or bone marrow function
The study team makes the final eligibility decision.
Where it's taking place
- Mexico
- Australia
- China
- United Kingdom
- Japan
- United States
- India
- Brazil
- Korea, Republic of
- Taiwan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Mexico; Australia; China; United Kingdom; Japan; United States and 4 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.